PMID- 35624958
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2076-3425 (Print)
IS  - 2076-3425 (Electronic)
IS  - 2076-3425 (Linking)
VI  - 12
IP  - 5
DP  - 2022 Apr 28
TI  - Grape-Seed-Derived Procyanidin Attenuates Chemotherapy-Induced Cognitive 
      Impairment by Suppressing MMP-9 Activity and Related Blood-Brain-Barrier Damage.
LID - 10.3390/brainsci12050571 [doi]
LID - 571
AB  - (1) Background: Chemotherapy-induced cognitive impairment (CICI) is often 
      observed in cancer patients and impairs their life quality. Grape-seed-orientated 
      procyanidin has been shown to have anti-inflammatory and neuroprotective effects, 
      yet its effects in preventing CICI have not been investigated. (2) Method: Adult 
      male mice received 2.3 mg/kg cisplatin or saline injections for three cycles 
      consisting of five daily injections followed by 5 days of rest. Procyanidin or 
      saline was administered 1 h prior to cisplatin treatment. Cognitive testing, 
      gelatin zymography, and blood-brain-barrier (BBB) penetration tests were 
      performed after treatment cessation. RAW264.7 cells were treated by stimulated 
      supernatant of SHSY5Y cells. In addition, high-mobility group protein B1 (HMGB1) 
      expression and MMP-9 activity were tested. (3) Results: Repeated cisplatin 
      treatment increased BBB penetration, MMP-9 activity, impaired performance in 
      contextual fear conditioning, and novel object recognition tasks. The knockout of 
      MMP-9 rescues cognitive impairment and cisplatin-induced upregulation of HMGB1 in 
      SHSY5Y cells. HMGB1/TLR4/IP3K/AKT signaling contributes to the increased MMP-9 
      activity in RAW264.7 cells. Procyanidin treatment attenuates MMP-9 activity, BBB 
      damage, and CICI. (4) Conclusions: The results indicated that MMP-9 activation 
      and BBB disruption is involved in CICI. Procyanidin may effectively alleviate the 
      harmful effects of cisplatin.
FAU - Song, Chao
AU  - Song C
AD  - Department of Oncology, First Affiliated Hospital of Soochow University, Suzhou 
      215006, China.
AD  - Department of Oncology, Shanghai East Hospital, Tongji University School of 
      Medicine, Shanghai 200120, China.
FAU - Gao, Chao
AU  - Gao C
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Xuzhou 221002, China.
FAU - Wang, Zhenxin
AU  - Wang Z
AD  - Department of Oncology, First Affiliated Hospital of Soochow University, Suzhou 
      215006, China.
LA  - eng
GR  - XYFY202110/Young Talent development Funding of the Affiliated Hospital of Xuzhou 
      Medical University/
PT  - Journal Article
DEP - 20220428
PL  - Switzerland
TA  - Brain Sci
JT  - Brain sciences
JID - 101598646
PMC - PMC9139059
OTO - NOTNLM
OT  - MMP-9
OT  - RAW264.7 cells
OT  - blood-brain barrier (BBB)
OT  - chemotherapy
OT  - chemotherapy-induced cognitive impairment (CICI)
OT  - cisplatin
OT  - procyanidin
COIS- The authors declare no conflict of interest.
EDAT- 2022/05/29 06:00
MHDA- 2022/05/29 06:01
PMCR- 2022/04/28
CRDT- 2022/05/28 01:03
PHST- 2022/02/25 00:00 [received]
PHST- 2022/04/22 00:00 [revised]
PHST- 2022/04/25 00:00 [accepted]
PHST- 2022/05/28 01:03 [entrez]
PHST- 2022/05/29 06:00 [pubmed]
PHST- 2022/05/29 06:01 [medline]
PHST- 2022/04/28 00:00 [pmc-release]
AID - brainsci12050571 [pii]
AID - brainsci-12-00571 [pii]
AID - 10.3390/brainsci12050571 [doi]
PST - epublish
SO  - Brain Sci. 2022 Apr 28;12(5):571. doi: 10.3390/brainsci12050571.